Trial Profile
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STOP-CO
- 01 May 2020 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.